Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28787193 | 0.93 | KMT2A (0.52) | KMT2AMEN1LMNATHRBBLM | |
| Isopropylamine SCHEMBL28787289 | 0.87 | LMNA (0.46) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL28787272 | 0.85 | KMT2A (0.44) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL28787218 | 0.82 | KMT2A (0.41) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL31192608 | 0.82 | POLB (0.71) | KMT2AMEN1LMNATHRBBLM | |
| Cyclopentanamine SCHEMBL28944901 | 0.81 | KMT2A (0.40) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL9732046 | 0.80 | LMNA (0.55) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL173014 | 0.80 | LMNA (0.55) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL18627019 | 0.80 | LMNA (0.55) | KMT2AMEN1LMNATHRBBLM | |
| SCHEMBL13893056 | 0.80 | LMNA (0.55) | KMT2AMEN1LMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874835-A1 | METHOD OF MAKING (S-(R*,R*))-3-METHYL-2-(3-OXO-3H-BENZO(D)ISOTHIAZOL-2-YL)PENTANOIC ACID AND (S-(R*,R*)), L-2-(2-(2-(1-CARBOXY-2-METHYLBUTYLCARBAMOYL)PHENYLDISULFONYL)BENZOYL-AMINO)-3-METHYLPENTANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1998-11-04 | — | — | EP | claimed |
| WO-1997022598-A1 | METHOD OF MAKING (S-(R*,R*))-3-METHYL-2-(3-OXO-3H-BENZO(D)ISOTHIAZOL-2-YL)PENTANOIC ACID AND (S-(R*,R*)), L-2-(2-(2-(1-CARBOXY-2-METHYLBUTYLCARBAMOYL)PHENYLDISULFONYL)BENZOYL-AMINO)-3-METHYLPENTANOIC ACID | WARNER-LAMBERT COMPANY (US) | 1997-06-26 | — | — | WO | claimed |
| US-5169961-A | Process for the production of 2-acetylbenzo [β]thiophenes | ABBOTT LABORATORIES (US) | 1992-12-08 | — | — | US | claimed |
| US-20230114304-A1 | DEPALMITOYLATING COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-04-13 | — | — | US | disclosed |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-03-28 | — | — | US | disclosed |
| CN-114478333-A | Synthetic method and application of 2, 2' -dithio-dibenzoyl formamide | 宜春新龙智慧高科有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-07-01 | — | — | US | disclosed |
| WO-2021030703-A1 | DEPALMITOYLATING COMPOSITIONS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-07-04 | — | — | US | disclosed |
| US-10166229-B2 | Compounds and methods for the treatment of cancer | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180296507-A1 | REDOX-ACTIVATED GLYCOCONJUGATED PROCHELATORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2018-10-18 | — | — | US | disclosed |
| US-5773433-A | ANXIOLYTICS AND ANTIDEPRESSANTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1998-06-30 | — | — | US | disclosed |
| EP-0789702-A1 | SUBSTITUTED TETRACYCLIC OXAZEPINE AND THIAZEPINE DERIVATIVES WITH 5-HT2 RECEPTOR AFFINITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-20 | — | — | EP | disclosed |
| EP-0775110-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996014321-A1 | SUBSTITUTED TETRACYCLIC OXAZEPINE AND THIAZEPINE DERIVATIVES WITH 5-HT2 RECEPTOR AFFINITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-17 | — | — | WO | disclosed |
| WO-1996004242-A1 | ARYLTHIO COMPOUNDS AS ANTIBACTERIAL AND ANTIVIRAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| US-5238997-A | Increased modulus without detrimental effect on age resistance and hysteresis | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1993-08-24 | — | — | US | disclosed |
| US-5169961-A | Process for the production of 2-acetylbenzo [β]thiophenes | ABBOTT LABORATORIES (US) | 1992-12-08 | — | — | US | disclosed |
| US-5169961-A | Process for the production of 2-acetylbenzo [β]thiophenes | ABBOTT LABORATORIES (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0173320-A1 | Substituted carbonylphenylsulfonyl guanidines | BAYER AG (DE) | 1986-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166229-B2 | Compounds and methods for the treatment of cancer | CASP3, CASP6, CASP5 | KMT2A 1515/4885MEN1 3608/4885LMNA 337/4885 |
| US-20190201394-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | CASP3, BAX, CASP6 | KMT2A 3132/4885MEN1 3135/4885LMNA 282/4885 |
| US-11612598-B2 | Compounds and methods for the treatment of cancer | CASP3, BAX, CASP6 | KMT2A 3132/4885MEN1 3135/4885LMNA 282/4885 |
| US-20210198269-A1 | INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) | SLC2A1, SLC2A3, SLC2A4 | KMT2A 3344/4885MEN1 913/4885LMNA 4641/4885 |
| US-20180296507-A1 | REDOX-ACTIVATED GLYCOCONJUGATED PROCHELATORS | SLC2A1, SLC2A2, SLC2A4 | KMT2A 3982/4885MEN1 2111/4885LMNA 3009/4885 |
| US-20230114304-A1 | DEPALMITOYLATING COMPOSITIONS AND THE USE THEREOF | LIPA, LCAT, SGMS2 | KMT2A 3348/4885MEN1 1805/4885LMNA 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.